https://www.selleckchem.com/pr....oducts/NVP-TAE684.ht
Biologic drugs have significantly improved the treatment of ulcerative colitis (UC) and Crohn's disease (CD). However, the availability of these drugs is limited by their high cost. Infliximab was the first biologic to be approved for inflammatory bowel diseases (IBD). After its patent expired other manufactures developed biosimilar versions, among which CT-P13, and licensed them thorough an expedite process. The aim of this review is to summarize the available evidence on CT-P13 use in IBD, with particular interest in the phase II t
Gefällt mir
Kommentar
Teilen
